Barclays
TCRT icon

Barclays’s Alaunos Therapeutics TCRT Stock Holding History

Barclays’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-447
Closed -$201K – 7678
2013
Q3 		$201K Sell
447
-120
-21% -$54.1K ﹤0.01% 5028
2013
Q2 		$179K Buy
+567
New +$157K ﹤0.01% 5288

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's TCRT Position: Q2 2026 in Review

Barclays opened a new position in Alaunos Therapeutics (TCRT) in Q2 2026: 15 shares worth $34. The stake represents ﹤0.01% of the portfolio and ranks #5265 among its holdings. This is a return to the name: Barclays previously reported a position in TCRT as recently as Q3 2025.

Barclays first reported a position in TCRT in Q2 2013 and has held it in 41 quarters since. The position peaked at $5.59M in Q4 2013. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • Barclays held 15 shares of Alaunos Therapeutics worth $34 as of Q2 2026.
  • Alaunos Therapeutics was a new Barclays position in Q2 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5265 holding.
  • Barclays first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • Barclays's Alaunos Therapeutics position peaked at $5.59M in Q4 2013.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.